🟢 Gilead Sciences Inc is trading 2.02% up today after FDA accepts its once-weekly HIV PrEP filing for Yeztugo

Gilead Sciences Inc is trading at $126.81 (+2.02%) today after the FDA accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) as a once-weekly oral HIV PrEP option.

• The FDA has established a target action date of February 2, 2027, following the initial announcement made on June 15.
• This regulatory acceptance serves as a direct company-specific catalyst, driving the stock's upward momentum in today's session.
• Yeztugo represents a potential breakthrough in HIV prevention by offering a more convenient once-weekly oral dosing schedule.